Calithera Biosciences FCF Yield

What does Calithera Biosciences do? Calithera Biosciences focuses on developing small molecule drugs targeting metabolic pathways in tumor and immune cells. The company's lead product candidate, CB-839, is a selective inhibitor of human glutaminase, targeting tumor cell metabolism. CB-1158, another candidate, is an orally bioavailable arginase inhibitor developed for hematology and oncology indications. These products are directed at critical metabolic pathways in the tumor microenvironment, aiming to disrupt tumor cell functions while supporting immune cell activity. The company develops these drugs for clinical use, with CB-839 and CB-1158 being the primary focus. CB-839 is being studied for its role in inhibiting glutaminase, a critical enzyme in tumor cells, while CB-1158 targets arginase to enhance anti-tumor activity in immune cells. Both products are in development for oncology applications, with CB-1158 showing single agent anti-tumor activity in preclinical models. Calithera Biosciences operates as a clinical-stage biopharmaceutical company, developing these small molecule drugs for therapeutic use. The company's revenue model is based on the development and potential future commercialization of CB-839 and CB-1158, targeting the oncology market with a focus on metabolic pathway disruption. The firm's product pipeline includes these two main candidates, which are being evaluated for their efficacy in cancer treatment. Calithera Biosciences is one of the most popular companies on Eulerpool.